Skip to main content

Table 3 Multivariate Cox proportional hazard analysis

From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

 

PFS

OS

 

HR (CI95)

P

HR (CI95)

P

Age

1.057 (0.984–1.135)

0.130

1.049 (0.981–1.121)

0.161

IPI

1.433 (0.365–5.620)

0.606

2.256 (0.580–8.767)

0.240

Rituximab induction

0.065 (0.011–0.367)

0.002

0.192 (0.041–0.890)

0.035

Upfront HD/ABSCT

0.318 (0.065–1.562)

0.158

0.498 (0.095–2.617)

0.410

Remission post first line therapy (non-CR versus CR)

0.106 (0.021–0.532)

0.006

0.156 (0.032–0.748)

0.020

Rituximab maintenance

0.444 (0.046–4.264)

0.482

0.360 (0.039–3.356)

0.370

  1. n = 76; ABSCT autologous blood stem cell transplantation, CI confidence interval, CR complete remission, HD high dose, HR Hazard ratio, IPI International Prognostic Index, OS overall survival, PFS progression free survival